The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

How we improved the treatment of Hodgkin lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
Sponsored

At City of Hope, our path to innovation includes surgical simulations in space, diverse genomics data—and more

Earlier this week at City of Hope, we celebrated World Cancer Day by announcing ambitious solutions to tackle some of the most pressing challenges in cancer care. This includes groundbreaking advancements in microbiome research aimed at improving cancer survival, increased emphasis on cancers that disproportionately affect women and people of color, and enhanced access to advanced cancer treatment.
By City of Hope
Byline
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account